PETER REISS, MD: And what was found out -- what was discovered is that particularly in patients who were already advanced, patients with AIDS, with established AIDS, is to some extent you could prevent new complications.
But, after a while it also became clear that the effect was transient.
ANNOUNCER: Over the course of several years, researchers developed other drugs like AZT.
Then, in the mid 1990s, another class of drugs became available, called Non-Nucleoside Reverse Transcriptase Inhibitors.
They, too, prevent the incorporation of viral genetic material into the host cell.
Also in the mid 1990s came the discovery of drugs called Protease Inhibitors, that work at a different point in the HIV replication cycle.
PETER REISS, MD: Protease inhibitors is different because they target a different viral enzyme which acts a later stage of the life cycle and importantly acts after this integration of DNA into the host genetic material.
ANDREW CARR, MD: Protease drugs don't stop the virus getting into your cells at all. What they do is they stop the cells producing new mature, healthy virus.
ANNOUNCER: It was only in the mid-1990s, with these many new drugs available, that doctors learned to combine three drugs at a time -- what's commonly known as HAART therapy.
This led to a dramatic change in patients' response to treatment.